2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer
暂无分享,去创建一个
Jie He | R. Rosati | P. Chiu | Haiquan Chen | Yong Li | F. Schlottmann | R. Mehta | L. Xue | S. Lloyd | K. Meredith | Y. Mao | Jian-ping Xu | L. Tan | K. Johung | J. Qin | Yin Li | Long-Qi Chen | Ke-Neng Chen | X. Kang | Chun Chen | M. Fu | Hecheng Li | M. Cecchini | Gaofeng Zhao | Cascinu Stefano | Jing Huang | Yongtao Han | Jian Hu | Z. Hui | Hongjing Jiang | N. Hirahara | N. Newman | Y. Liao | Shaohua Ma | Zhigang Li | Shiping Guo | G. Qiao | Yue-Feng Jiang | Rui-xiang Zhang | Yang Liu | Xin Wang | Mingqiang Kang | Shuoyan Liu | Zhen Wang | Qingfeng Zheng | Hui Tian | Junke Fu | Qing-Hui Geng | Taiqian Gong | Yiyang He | Jie Jiang | Jianqun Ma | S. Li | Jun Zhao | S. Zheng | Yong’an Zhou | Magnus Nilsson | Dae Joon Kim | Shan Li | Jian‐ping Xu | Yongtao Han | Yi He | Yongtao Han
[1] Kisha Mitchell,et al. Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Ajani,et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. , 2021 .
[3] J. Ajani,et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. , 2021, The New England journal of medicine.
[4] W. Mao,et al. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, Annals of surgery.
[5] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[6] E. D. Geijsen,et al. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT) , 2021, Clinical Cancer Research.
[7] S. Yeung,et al. Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma. , 2021 .
[8] Q. Fan,et al. Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. , 2021, Journal of Clinical Oncology.
[9] Yuyan Zheng,et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). , 2020, European journal of cancer.
[10] David R. Jones,et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. , 2020, The Journal of thoracic and cardiovascular surgery.
[11] Mengxia Li,et al. 415 Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study , 2020, Journal for ImmunoTherapy of Cancer.
[12] N. Sun,et al. 175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC) , 2020 .
[13] Sung-Bae Kim,et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Ajani,et al. LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study , 2020 .
[15] M. Shah,et al. LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study , 2020 .
[16] Y. Hu,et al. 1058P A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC) , 2020 .
[17] J. Ajani,et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study , 2020 .
[18] S. Oh,et al. LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study , 2020 .
[19] Jian-Hua Fu,et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. , 2020, European journal of cancer.
[20] David T. W. Tzeng,et al. The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer , 2020, Cancer Immunology Research.
[21] Y. Ba,et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.
[22] Joe Y. Chang,et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Shu-geng Gao,et al. Analysis of a registry database for esophageal cancer from high-volume centers in China. , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[24] H. Ishwaran,et al. Value of Lymphadenectomy in Patients Receiving Neoadjuvant Therapy for Esophageal Adenocarcinoma. , 2019, Annals of surgery.
[25] D. Altmann,et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.
[26] M. Westerhoff,et al. Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey , 2019, Modern Pathology.
[27] H. Daiko,et al. FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma , 2019, Annals of Oncology.
[28] Sung-Bae Kim,et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[29] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[30] Jong Hoon Kim,et al. A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). , 2019, Journal of Clinical Oncology.
[31] F W MULSOW,et al. Cancer incidence and mortality , 2019, Health at a Glance: Europe.
[32] R. Hales,et al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. , 2019, Journal of Clinical Oncology.
[33] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[34] S. Perkins,et al. Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study. , 2018 .
[35] J. Brahmer,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.
[36] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[38] S. Barni,et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[39] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[40] A. Giobbie-Hurder,et al. Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.
[41] Y. Qiao,et al. Occupational and environmental cancer incidence and mortality in China. , 2012, Occupational medicine.
[42] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[43] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[44] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[45] Jeffrey S. Morris,et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation , 2005, Cancer.
[46] H. Höfler,et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.
[47] G. Noël,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy , 2002 .
[48] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[50] N. Dalkey,et al. An Experimental Application of the Delphi Method to the Use of Experts , 1963 .
[51] H. Ishwaran,et al. Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.